Key Takeaways:

  • FDA proposes permanently excluding semaglutide, tirzepatide, and liraglutide from 503B bulk compounding list, citing no clinical need
  • Public comment period runs through June 29, 2026, before final determination
  • Move would close the last pathway for large-scale compounding even if future shortages occur
  • Small-scale individual patient compounding may still be possible under limited circumstances

The FDA has opened a critical public comment period that could permanently end large-scale compounding of the most popular GLP-1 weight loss medications. The agency announced it is proposing to exclude semaglutide, tirzepatide, and liraglutide on the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances.

This proposal represents the FDA's most decisive move yet against affordable GLP-1 alternatives. Unlike the previous shortage list removals that were temporary measures tied to supply availability, this action would permanently block large-scale compounding regardless of future market conditions.

How the 503B Bulk List Works

The 503B bulks list identifies bulk drug substances that outsourcing facilities may use in compounding under the conditions of section 503B of the Federal Food, Drug, and Cosmetic Act. In most cases, outsourcing facilities cannot compound drugs using bulk drug substances unless the substance appears on the 503B bulks list, or the compounded drug is on the FDA's drug shortage list at the time of compounding, distribution, and dispensing.

Currently, tirzepatide and semaglutide do not appear on either the 503B bulks list or the drug shortage list. The FDA's proposal would formally exclude these substances from ever being added to the bulks list.

After evaluating the nominations for these three substances, the FDA did not identify a clinical need for outsourcing facilities to compound semaglutide, tirzepatide, and liraglutide from bulk drug substances.

What's Different About This Action

This proposal goes beyond the agency's previous enforcement actions. The significance of this proposal is that it would close one of the few remaining legal avenues for 503B outsourcing facilities to be able to resume large-scale compounding of these drugs.

A formal exclusion would foreclose any future pathway for bulk compounding, even in the event of a new shortage designation. This means even if brand-name manufacturers face supply problems again, large compounding operations wouldn't be able to step in as they did during the 2022-2025 shortage period.

The compounding market that emerged during the shortage offered these medications at dramatically lower prices. Demand-driven shortages beginning in 2022 enabled widespread compounding at approximately $150 to $300 per month versus more than $1,000 branded pricing.

Safety Concerns Drive FDA Position

Patient safety data has played a central role in the FDA's increasingly aggressive stance. As of early 2025, the FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 reports associated with compounded tirzepatide, many involving dosing errors from patients self-administering incorrect doses from multidose vials—some of which required hospitalization.

The agency has also raised concerns about product quality. Litigation by Novo Nordisk alleges some compounded semaglutide contained impurities up to 86%, highlighting risks of contamination, variable potency, and severe hypersensitivity reactions including anaphylaxis.

Recent enforcement actions have intensified these concerns. Over the past 6 months, the agency has sent thousands of warning letters to various firms, a volume that exceeds the total number sent over the previous decade.

Impact on Small-Scale Compounding

This proposal does not directly alter the legal framework for 503A compounding pharmacies. Section 503A pharmacies operate under a separate statutory provision and compound drugs pursuant to individual patient-specific prescriptions under state board of pharmacy oversight. They do not rely on the 503B bulks list to authorize their compounding activities.

However, options remain extremely limited. There may still be limited use under 503A compounding rules, where a medication is prepared for an individual patient based on a specific clinical indication, but that pathway is much more restricted and not designed for widespread use.

For 503A pharmacies, narrow exceptions still exist—such as documented excipient allergies or the need for a dose strength not commercially available—but routine patient-specific compounding that amounts to essentially a copy of an approved product remains off-limits.

Your Window to Weigh In

The FDA is now inviting interested parties to submit comments electronically through the docket by June 29, 2026. The agency will consider submitted comments before making a final determination.

Healthcare organizations are already preparing their responses. Organizations including the National Community Pharmacists Association and the Alliance for Pharmacy Compounding are expected to file comments.

Healthcare providers with relevant perspectives are encouraged to submit comments through the federal docket before the June 29, 2026, deadline.

What This Means for You

If you've been relying on compounded GLP-1 medications or considering them as an affordable option, this proposal could permanently close that door. The comment period represents the last opportunity for public input before the FDA makes its final decision.

While large-scale compounding may end, you still have options for affordable GLP-1 access. Manufacturer savings programs, Medicare coverage expansions, and telehealth providers offering brand-name medications at competitive prices continue to evolve. Before assuming brand-name medications are unaffordable, compare your options using current savings programs and insurance benefits.

You can also explore working with qualified clinics in your area that specialize in GLP-1 treatments and understand the various cost-saving programs available. Many clinics can help you navigate manufacturer discount programs, insurance prior authorizations, and alternative payment options.

The regulatory landscape is shifting rapidly, but it's moving toward ensuring you receive medications that have undergone full FDA review for safety and effectiveness. While this may mean higher costs for some, it also means greater confidence in the quality and consistency of your treatment.

Sources: